A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with Post-hoc biomarker analysis
一项评估新型局部用GPCR19介导的炎症小体抑制剂NuGel治疗轻度至中度特应性皮炎患者的疗效和安全性的IIa期双盲、安慰剂对照、随机临床试验：一项概念验证研究及事后生物标志物分析
期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2025.1560447
Baek, Gyeong Ho; Kim, Bo Ri; Shin, Jung-Won; Huh, Chang Hun; Hwang, Jungjoong; Ko, Sungmin; Kim, Siwon; Ho, Pil-Su; Kim, Kyu-Han; Park, Chun Wook; Seo, Seong Jun; Park, Chang-Ook; Shin, Dongyoon; Kim, Yeongshin; Kim, Youngsoo; Seong, Seung-Yong; Na, Jung-Im
CR1
炎症
炎性小体
炎症/感染
GPCR/Calcium/cAMP
炎性小体
免疫/内分泌
